Adhesion Molecules Associated with Female Genital Tract Infection

Jamal Qualai1*, Jon Cantero1*, Lin-Xi Li2, José Manuel Carrascosa3, Eduard Cabré4,5, Olga Dern6, Lauro Sumoy7, Gerard Requena8, Stephen J. McSorley9, Meritxell Genescà1*

1 Mucosal Immunology Unit, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain, 2 Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America, 3 Department of Dermatology, University Hospital “Germans Trias i Pujol,” Badalona, Universitat Autònoma de Barcelona, Spain, 4 Department of Gastroenterology, University Hospital “Germans Trias i Pujol,” Can Ruti Campus, Badalona, Catalonia, Spain, 5 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain, 6 Atención Salud Sexual y Reproductiva (ASSIR), Centre d’Atenció Primària (CAP) Sant Fèlix, Institut Català de la Salut (ICS), Sabadell, Spain, 7 Genomics and Bioinformatics Group, Institute for Predictive and Personalized Medicine of Cancer (IMPPC), Can Ruti Campus, Badalona, Spain, 8 Flow Cytometry Unit, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain, 9 Center for Comparative Medicine (CCM), Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America

These authors contributed equally to this work.

*mgenesca@igtp.cat (MG)

Abstract

Efforts to develop vaccines that can elicit mucosal immune responses in the female genital tract against sexually transmitted infections have been hampered by an inability to measure immune responses in these tissues. The differential expression of adhesion molecules is known to confer site-dependent homing of circulating effector T cells to mucosal tissues. Specific homing molecules have been defined that can be measured in blood as surrogate markers of local immunity (e.g. α4β7 for gut). Here we analyzed the expression pattern of adhesion molecules by circulating effector T cells following mucosal infection of the female genital tract in mice and during a symptomatic episode of vaginosis in women. While CCR2, CCR5, CXCR6 and CD11c were preferentially expressed in a mouse model of Chlamydia infection, only CCR5 and CD11c were clearly expressed by effector T cells during bacterial vaginosis in women. Other homing molecules previously suggested as required for homing to the genital mucosa such as α4β1 and α4β7 were also differentially expressed in these patients. However, CD11c expression, an integrin chain rarely analyzed in the context of T cell immunity, was the most consistently elevated in all activated effector CD8+ T cell subsets analyzed. This molecule was also induced after systemic infection in mice, suggesting that CD11c is not exclusive of genital tract infection. Still, its increase in response to genital tract disorders may represent a novel surrogate marker of mucosal immunity in women, and warrants further exploration for diagnostic and therapeutic purposes.
Introduction

Female genital tract (FGT) infections, including common sexually transmitted infections (STI), seriously compromise the health of women. Worldwide, more than 340 million new cases of treatable STI occur each year and they are estimated to be the leading cause of morbidity in women in developing countries [1]. Furthermore, pre-existing FGT infections affect the development and pathogenesis of other STI, as occurs with the pro-inflammatory environment generated by bacterial vaginosis (BV) and the enhancement of human immunodeficiency virus (HIV) replication [2]. The long-term consequences of STI, including pelvic inflammatory disease, cancer, infertility, stillbirth, etc. not only are highly relevant at the social and health level, but also have a major economic impact.

Although effective vaccines exist for human papilloma virus and hepatitis B virus, efforts to develop vaccines against herpes simplex virus type 2 (HSV-2), HIV and bacterial STI have been hampered by an inability to effectively measure immune responses in the genital tract. Such vaccines need to be able to generate robust immune responses at site of potential exposure in order to provide rapid control of primary infection [3, 4]. Mucosal T cells and, notably, cytotoxic T lymphocytes play a critical role in the clearance of sexually transmitted pathogens [4]. For instance, studies in human have confirmed the association of T cell-mediated immunity with clearance of Chlamydia infection [5] and susceptibility to re-infection [6]. Moreover, the presence of antiviral effector CD8+ T cells in the vagina of immunized monkeys correlates with protection from uncontrolled viremia after pathogenic challenge with simian immunodeficiency virus [7]. In these models of genital infection, the induction of effector memory T (T_{EM}) cells and antibodies that are able to mount fast responses upon re-challenge is critical to control the pathogen. However, current assays used to understand the magnitude and quality of immune responses in the FGT rely primarily on blood samples and thus provide an incomplete picture of localized immune control.

The capacity of distinct subsets of antigen-experienced lymphocytes to traffic preferentially into specific compartments is termed homing. T_{EM} cell entry into inflamed non-lymphoid tissues is an active process involving members of the integrin, selectin-ligand and chemokine-receptor families, which mediate selective interactions of circulating lymphocytes with the specialized vascular endothelium [8]. While some adhesion molecules are enriched for a given tissue, e.g. α4β7 integrin and CC chemokine receptor CCR9 are associated with homing of T cells to the gut and cutaneous lymphocyte-associated antigen (CLA) and CCR4/CCR10 with T cell homing to the skin, other molecules are specialized for tissue-inflammatory functions to multiple tissues, such as CXCR3 or αLβ2 [9, 10]. Importantly, many properties that enable T cells to traffic to specific locations are programmed during the early stages of the infection [11]. Analysis of blood samples during the primary immune response to yellow fever immunization in humans suggests that human virus-specific CD8+ T cells express a dynamic pattern of homing molecules early after immune activation [12]. Thus, analysis of lymphocytes in blood will not reflect the quantity/quality of non-recirculating resident memory T cells [11], and sampling directly from mucosal surfaces will be required to define correlates of protection after vaccination. However, after activation, there is a window of opportunity to examine circulating lymphocytes in blood as they are homing to a specific mucosal tissue.

In contrast to the gastrointestinal tract or the skin, our understanding of homing receptors that are required for cells migrating to the FGT is limited. α4β7 was proposed to recruit CD4+ T cells to the vaginal mucosa of mice infected with Chlamydia [13]. Yet, a recent paper demonstrated that this integrin is not necessary for CD4+ T cell-mediated protection against Chlamydia trachomatis infection, while α4β1 appears to drive homing of protective cells into the murine upper genital tract [14]. Other papers using animal models support these findings [15].
and expression of vascular cell adhesion molecule-1, which binds this integrin, has been
detected in the human vagina [16, 17]. Nonetheless, another recent paper demonstrated that
circulating CD4+ T cells from asymptomatic HSV-2-infected patients express higher levels of
α4β7 than uninfected patients [18]. Lastly, other investigators have described homing receptors
that are shared between immune cells migrating to the skin and the FGT [16, 19]. Here, we
hypothesized that defining the homing profiles of lymphocytes migrating towards the genital
tract could potentially be used as a surrogate marker of FGT immunity. We found that TEM
cells from mice intravaginally-infected with *Chlamydia muridarum* expressed high levels of
CCR2, CCR5, CXCR6 and CD11c. When comparing these homing profiles to women with dif-
ferent mucosal or skin disorders, unique features were detected in each of the cohorts, com-
pared to healthy patients. Of particular interest, CD11c was strikingly increased in CD8+ TEM
cells from patients with BV and thus could serve as a novel indirect marker of FGT immunity.

**Materials and Methods**

**Ethics statement**

All mice were maintained in accordance with the recommendations of the Association for
Assessment and Accreditation of Laboratory Animal Care International Standards and with
the recommendations in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The Institutional Animal Use and Care Committee of the University of
California, Davis, approved these experiments (Protocol # 18299).

Informed written consent was obtained from all participants and the study protocol and ques-
tionnaire was approved by the University Hospital Germans Trias i Pujol (HUGTP, Badalona,
Spain) Clinical Research Ethics Committee (reference # EO-11-074). The study was undertaken
in accordance with the Declaration of Helsinki and the requirements of Good Clinical Practice.

**Animal model**

*Chlamydia muridarum* strain Weiss was purchased from ATCC (Manassas, VA) and propa-
gated in HeLa 229 cells in Dulbecco’s modified Eagle’s medium (Life Technologies, Grand
Island, NY) supplemented with 10% fetal bovine serum (FBS). *C. muridarum* elementary bod-
ies (EBs) were purified by discontinuous density gradient centrifugation as previously
described and stored at -80°C [20]. The number of inclusion-forming units of purified EBs was
determined by infection of HeLa 229 cells and enumeration of inclusions that were stained
with anti-*Chlamydia* major outer membrane protein antibody (a kind gift from Dr. Harlan
Caldwell). Eight weeks old C57BL/6 mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). For systemic infection, mice were intravenously (IV) injected in the lateral tail
vein with 1x10⁵ C. muridarum. For vaginal infection, estrus was synchronized by subcutaneous
injection of 2.5 mg medroxyprogesterone acetate (Greenstone, NJ). Seven days after, 1x10⁵ C.
muridarum in 5μL sucrose/phosphate/glutamate buffer were deposited directly into the vaginal
vaults with a blunted pipet tip [21]. Seven, 10 and 14 days post-infection, blood was collected
by retro-orbital bleeding. Immediately after collection, blood samples for cell sorting and vali-
dation analyses were air-shipped from the laboratory of Dr. McSorley (CCM, UC Davis, CA)
to the laboratory of Dr. Genescà (IGTP, Badalona, Spain). Samples arrived refrigerated and in
good conditions 48 hours later and were immediately processed.

**Cell sorting**

Circulating TEM cells were sorted from six 7 days *Chlamydia*-infected mice (VAG group) and
six contemporary sham-treated mice (control group). Blood samples (~500μl) were
immediately lysed using an in-house red blood cell lysis buffer. After washing, cells were stained with antibodies against CD3-Vioblue (145-2C11), CD62L-PE (MEL-14-H2.100) and CD44-FITC (IM7.8.1; all from Miltenyi Biotec, Madrid, Spain). Cells suspended in cold FACS flow buffer (0.5% FBS-PBS with 0.5mM EDTA) were immediately sorted into 350μl of chilled RLT buffer (QIAGEN, Valencia, CA) using a BD FACSARia™ Cell Sorter (Flow Cytometry Platform, IGTP). Purity of sorted CD62L−CD44+ activated TEM cells was >99%. Once sorted, samples were mixed for a minute and after a short spin, the volume of RLT was adjusted (3.5:1 ratio of RLT to sheath fluid) using filtered tips. Samples were mixed and spun again and immediately frozen at -80°C.

Gene expression analyses
Total RNA was isolated from cells using RNA easy Mini kit (QIAGEN). After qualitative assessment of RNA integrity, samples were amplified using Whole Transcriptome Amplification 2 (Sigma-Aldrich, Madrid, Spain). We chose four samples in each group that qualified for microarray analyses, yet one sample from the VAG and control group were discarded after as outliers, thus microarray analyses were performed in n = 3 for the VAG group and n = 3 for the control group (which were actually contemporary samples). The number of sorted cells in each group was similar (15,207 ± 2,339 cells for the VAG group and 20,793 ± 2,443 cells for the control group; not significant).

Affymetrix microarray hybridization was performed using the Mouse Genome 430 PM Strip platform. Images intensities were extracted using GeneAtlas System software (Affymetrix), normalized and summarized using Robust Multi-array Average algorithm. Differential gene expression analysis was assessed by fitting to an empirical Bayesian linear model. Statistical significance in differential gene expression was computed with a false discovery rate multiple testing adjustment correction. For this analysis we used the Limma package and the R statistical programming environment [22]. The ‘compute overlaps’ function in the ‘investigate gene sets web application (http://www.broadinstitute.org/gsea/msigdb/annotate.jsp) of the Molecular Signatures Database v4.0 (MaSigDB) was used to explore functions enriched among the top regulated genes defined as having a nominal (non-adjusted) p-value <0.005. The lists of gene symbols up-regulated and down-regulated in infected versus uninfected samples were scrutinized for significant overlaps with pathway (C2: CP, KEGG) and immunologic signatures (C7) in MaSigDB [23].

Flow cytometry validation analyses in mice
Blood samples (~500μl) were immediately lysed, washed, suspended in PBS and incubated with Aqua vital dye to distinguish live from dead cells (Invitrogen, Burlington, ON, Canada). Following two more washes, cells were suspended in washing and staining buffer (1% bovine serum albumin-PBS) and incubated for 20 minutes with the following cocktail of pre-titrated anti-mouse antibodies: CD3-Vioblue (145-2C11), CD4-APC-H7 (GK1.5), CD62L-PE (MEL-14-H2.100) (Miltenyi Biotec), CD44-Brilliant Violet 570 (IM7; BioLegend, San Diego, CA), CD11c-PE-Cy7 (HL3; BD Biosciences) and CCR5-FITC (CTC5), CXCR6-PerCP (221002) and CCR2-APC (475301) (R&D Systems Inc., Minneapolis, MN). All events were acquired in a BD FACSARia™ Cell Sorter and analyzed with FlowJo vX.0.7 software (TreeStar, Ashland, OR).

Participant enrolment and inclusion criteria for human samples
All participants for this study (20–40 year old women) were classified in the following different cohorts: normal donors (ND, n = 13, median age of 25 years with interquartile range (IQR) of 23–28 years), psoriasis (PS, n = 5, median of 35 with IQR 30–37), ulcerative colitis (UC, n = 4,
median of 26 with IQR 22–38), and BV (n = 5, median of 30 with IQR 25–36). Healthy ND volunteers were recruited from the clinical trials unit of the University Hospital Germans Trias i Pujol (HUGTP, Badalona, Spain). Patient recruitment for the PS and UC cohorts was carried in the corresponding services of Dermatology and Gastroenterology of the HUGTP. BV patients were recruited at the Unit of Attention to Sexual and Reproductive Health from the Primary Health Care centers of Sabadell and Cerdanyola in Catalonia (Spain).

Participants completed a questionnaire in order to detect possible exclusion criteria (other chronic or acute diseases, allergies or infections, immunosuppressive treatment, etc.) and register menstrual cycle and birth control data. Patients included in each cohort presented either an active burst (for PS and UC groups) or symptoms compatible with a recent infection within the last 7 days (for BV group). Inclusion criteria for the PS group consisted on women with active psoriasis vulgaris that suffered a relapse of less than two weeks, with no treatment for at least six weeks. UC subjects were women with active ulcerative colitis: the extent of pathology was defined based on the Montreal classification [24] and the severity of disease on the Mayo’s Disease Activity Index [25]. Only patients with active burst (index >9) off immunosuppressive treatment were included. Lastly, not-treated and symptomatic BV infections defined by Nugent scoring of >7 and suspected of Gardnerella vaginalis origin were confirmed by microscopic examination (more than 20% of clue cells). Patients with other STIs were excluded.

Human T cell phenotype

Blood was collected and processed within 4 hours maximum. An ammonium chloride-based lysing reagent (BD Pharm Lyse, BD Biosciences) was used for erythrocyte deletion of 1ml of blood. After washing, cells were suspended in PBS and stained with Aqua Dye (Invitrogen) for cell viability. Cells were washed again, suspended in staining buffer and divided in four tubes. The four different panels assessed contained some common and some specific antibodies. Common antibodies were: CD3-eFluor 605, CD4-Alexa700 (eBioscience, San Diego, CA), CCR7-Horizon PE-CF594, CD38-Brilliant Violet 421, HLA-DR-PerCP-Cy5.5 and CD11c-PE-Cy7 (BD Biosciences). Specific for each panel were: 1) CCR2-PE, CCR5-APC-Cy7, CXCR6-APC (R&D Systems Inc.) and CXCR3-FITC (BioLegend); 2) CD49d (α4)-FITC, β7-APC, CCR9-PE (BD Biosciences) and CD29 (β1)-APC-Cy7 (BioLegend); 3) CD103-FITC, CD54-APC, CD49a (α1)-PE and CD29-APC-Cy7 (BioLegend); 4) CD18-APC, CLA-FITC (BD Biosciences) and CCR10-PE (BioLegend). Cells were acquired using a BD LSRFortessa SORP flow cytometer (Flow Cytometry Platform, IGTP) and analyzed with FlowJo 9.3.2 software (TreeStar). Gates were drawn based on fluorescence minus one-controls and isotypes, and CD3+ CD4- phenotype was considered CD8+ T cells.

Tissue processing and flow cytometry

Mouse spleen and iliac lymph nodes were harvested and a single-cell suspension prepared. Peripheral blood was collected by retro-orbital bleeding. Red blood cells were removed by ACK lysing buffer (Life Technologies). Leukocytes were washed with FACS buffer (PBS with 2% FBS) and stored on ice until use. Mouse genital tract were removed and leukocytes isolated as described [26]. Briefly, mouse genital tract (vagina, cervix, uterine horns, oviducts) were minced into small pieces, digested in 500mg/L collagenase IV (Sigma) for 1 hour at 37°C with constant stirring. Leukocytes were purified by percoll density gradient centrifugation (GE Healthcare), washed with FACS buffer and stored on ice until use.

Single cell suspensions from spleen, dLNs, blood and genital tract were prepared in FACS buffer and blocked with Fc block (culture supernatant from the 24G2 hybridoma, 2% mouse serum, 2%, rat serum, and 0.01% sodium azide). Cells were then stained with anti-CD11b,
F4/80 and B220-FITC together with MHCII PerCP-Cy5.5 (as dump channels), CD4-APC-eFluor780, CD8-Pacific Orange, CD44-Alexa 700 and CD11c-APC. All flow antibodies were obtained from eBiosciences. Samples were acquired on an LSRFortessa flow cytometer and analyzed using FlowJo software (TreeStar).

**Statistical Analysis**

Data are reported as the median and IQR for each animal group or cohort using Prism 4.0 software (GraphPad Software). Statistical analyses were performed by non-parametric Mann Whitney test to compare single time points between two groups (case vs. control) using SPSS software for Windows version 13.0 (Chicago, IL). P value of <0.05 was considered significant.

**Accession codes**

Microarray data presented in this article are deposited into the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE67147.

**Results**

**Differentially expressed genes after genital tract infection in mice**

To address the homing profile of TEM cells shortly after vaginal infection, blood CD3+ CD62L- CD44+ T cells were sorted from *Chlamydia*-infected mice (VAG group) and sham-treated mice (control group) 7 days post-infection in a pilot experiment. After qualitative assessment of the sample RNA integrity and amplification, we chose three samples in each group that qualified for microarray analyses. We detected highly significant differences in genes involved in interferon signaling, synthesis of DNA, cell cycle and activation of the immune system between the two groups (Table 1). Regarding adhesion molecules, several chemokine receptors and integrin genes were significantly up-regulated in infected animals compared to the control group and the four most significant genes were selected for further validation: Ccr5, Itgax, Cxcr6 and Ccr2 (Fig 1).

**Higher frequency of circulating CD11c+ CD8+ T cells is detected early after Chlamydia infection**

In order to confirm the expression of these molecules, we analyzed a 10-color panel by flow cytometry at 7, 10 and 14 days post-infection. In general, the percentage of CCR2, CCR5, CXCR6 and CD11c (Itgax) in live CD4+ or CD4- (putative CD8+) T cells peaked 10 days after infection, when in most cases their total frequency was significantly higher than in the control group (S1 Fig). Of note, there was a significant increase in the frequency of TEM cells (CD62L-) in the VAG groups compared to control animals. While CD4+ T cells only had a significant increase in the percentage of CD44+ activated TEM cells (S1e Fig), CD8+ T cells demonstrated a significant increase in both, CD44+ and CD44- subsets after infection (S1e and S1f Fig). When analyzing the expression of the selected homing molecules in the activated TEM cell subset, there was a higher percentage of CCR5, CCR2 and CD11c in the CD44+ CD44- TEM cells at 10 and/or 14 days post-infection than in the control group (Fig 2a, 2g, 2e and 2c). In contrast, we detected a higher percentage of CXCR6 seven days after infection and of CD11c at all-time points in the CD8- CD44+ TEM cells compared to the control group (Fig 2e and 2g). Although expression of these markers was also increased in the non-activated fraction of both TEM cell subsets, the magnitude of expression was much lower (Fig 2b, 2d, 2f and 2h). Thus, all the selected up-regulated genes were confirmed by protein expression. While CCR2 and CCR5
were only increased in the CD4+ TEM cell subset after infection, expression of CXCR6 and CD11c was much more abundant in CD8+ TEM cells.

**CD11c expression increases in human circulating CD8+ TEM during symptomatic vaginosis**

We next addressed the expression of these and other potentially relevant mucosal homing molecules in peripheral blood T_{EM} cells from healthy young women (ND) in comparison to women with psoriasis (PS), ulcerative colitis (UC) and BV. First, we analyzed the expression of the different molecules by CD4+ and CD4- (putative CD8+) T cells in CCR7- TEM cells from thirteen ND, as shown in the general gating strategy (Fig 3 and S2 Fig). All these molecules were also analyzed based on the activation markers included (CD38/HLA-DR) in order to detect associations between them. We observed a higher percentage of circulating CCR7- CD4+ T cells expressing the CCR2, CCR9 and CCR10 chemokine receptors compared to CD4- T cells, while there was a higher percentage of circulating CD8+ TEM cells expressing CCR5 and CXCR6 compared to CD4+ TEM cells (Fig 4). Regarding integrins and other molecules, the frequency of α1β1, α4β7 and CLA was in general higher in CD4+ TEM cells than in CD8+, while the frequency of α4β1 and CD11c was higher in CD8+ TEM cells (Fig 4). Finally, the frequency

| Gene Set Name | # Genes in Gene Set (K)a | Description | # Genes in overlap (k)b | k/Kc | FDRd q-value |
|---------------|--------------------------|-------------|-------------------------|------|--------------|
| REACTOME_SYNTHESIS_OF_DNA | 92 | Genes involved in Synthesis of DNA | 7 | 0.0761 | 7.02E-05 |
| REACTOME_INTERFERON_SIGNALING | 159 | Genes involved in Interferon Signaling | 8 | 0.0503 | 7.02E-05 |
| REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIM_GENES | 66 | Genes involved in Antiviral mechanism by IFN-stimulated genes | 6 | 0.0909 | 7.02E-05 |
| REACTOME_S_PHASE | 109 | Genes involved in S Phase | 7 | 0.0642 | 7.02E-05 |
| REACTOME_IMMUNE_SYSTEM | 933 | Genes involved in Immune System | 16 | 0.0171 | 1.33E-04 |
| PID_TCPTP_PATHWAY | 43 | Signaling events mediated by TCPTP | 5 | 0.1163 | 1.33E-04 |
| REACTOME_CELL_CYCLE | 421 | Genes involved in Cell Cycle | 11 | 0.0261 | 1.33E-04 |
| REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM | 270 | Genes involved in Cytokine Signaling in Immune system | 9 | 0.0333 | 1.69E-04 |
| REACTOME_CELL_CYCLE_MITOTIC | 325 | Genes involved in Cell Cycle, Mitotic | 9 | 0.0277 | 6.65E-04 |
| REACTOME_DNA_STRAND_ELONGATION | 30 | Genes involved in DNA strand elongation | 4 | 0.1333 | 6.65E-04 |
| REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX | 31 | Genes involved in Activation of the pre-replicative complex | 4 | 0.129 | 6.92E-04 |
| REACTOME_DNA_REPLICATION | 192 | Genes involved in DNA Replication | 7 | 0.0365 | 1.02E-03 |

\[a\] K indicates the number of genes in the set from MSigDB.

\[b\] k indicates the number of genes in the intersection of the query set with a set from MSigDB.

\[c\] k/K indicates the proportion of gene set genes present in the query set.

\[d\] FDR corresponds to false discovery rate.

doi:10.1371/journal.pone.0156605.t001
of CXCR3 did not show any differences between these subsets, while CD103 was only higher in the HLA-DR+ fraction of circulating CCR7- CD4+ T cells compared to CD8+ T cells (S4 Fig).

Next we compared the expression of these adhesion molecules in ND with their expression in different mucosal and skin disorders. Of note, there was an overall decrease of the percentage of CD4+ T cells in the different groups of patients that was only significant for the BV cohort (S5 Fig). When analyzing the TEM cell fractions, we detected a significant increase in at least one of the activation markers in each cohort, which denoted the pathological condition of the patients (Fig 5). The comparison on the expression of the different adhesion molecules was performed in the TEM cell fraction as a total (S6 Fig), as well as in each of the activated fractions (S7 and S8 Figs). The main findings in total fractions were a general decrease on the frequency of CCR2 in CD4+ TEM cells and an increase on the frequency of CCR10 in CD8+ TEM cells from all groups of patients (S6 Fig). Also, there was a significant increase on the percentage of α1β1 expression in CD8+ TEM cells from the PS group and a decrease on the percentage of CLA in the same cells compared to ND (S6c Fig). The UC group presented an increase on the percentage of α1β1 expression in CD8+ TEM cells (S6d Fig), while the BV group had an increase on CCR5 and α4β1 expression in CD4+ TEM cells and of CD11c in CD8+ TEM cells when compared to ND (S6 Fig).

Since activated TEM cells more likely contain specific T cells migrating towards the inflamed tissues [27], we focused on the differences detected in the double activated fraction (Fig 6). This way, the only significant changes within CD38+ HLA-DR+ TEM cells from the PS group compared to ND were: increased frequency of CCR9 in CD8+ TEM cells, increased frequency of α1β1 in CD4+ TEM cells, and a significant decrease of α4β1 and α4β7 in CD8+ TEM cells.
Fig 2. Kinetics of CCR2, CCR5, CXCR6 and CD11c frequency after vaginal Chlamydia infection in mice. The frequency of CCR5 (a, b), CCR2 (c, d), CXCR6 (e, f) and CD11c (g, h) was determined in activated CD44+ (left graphs) and CD44- (right graphs) effector memory T (TEM) cells from blood by flow cytometry at 7, 10 and 14 days after vaginal infection with C. muridarum in mice. After gating on live CD3+ cells and CD4+ or CD4- (putative CD8+) T cells, the frequency of CCR5, CCR2, CXCR6 and CD11c was quantified in the CD62L-
CD44+/CD44- T cell subsets. Each time point represents the median ± interquartile range of three or seven infected animals and all controls (n = 12).

doi:10.1371/journal.pone.0156605.g002

Fig 3. Gating strategy and representative plots of adhesion molecule analysis in circulating TEM cells from women. The overall gating strategy for a representative single normal donor is shown. (a) General gating strategy for effector memory T (TEM) cells consist of the following consecutive gates: lymphocytes, singlets and live CD3+ T cells (top row); CD4+ and CD4- (putative CD8+) T cells, and the effector CCR7- fraction for each of these subsets (bottom row). (b) Representative plots of molecules analyzed in TEM cells in one of the panels are shown: activated CD38 and/or HLA-DR TEM cells, expression of CCR5 and CCR2, expression of CXCR6, and expression of CXCR3 and CD11c for CD4+ TEM cells (top row) and CD8+ TEM cells (bottom row). Isotype controls are shown in S3 Fig.

doi:10.1371/journal.pone.0156605.g003
Fig 4. Comparison of adhesion molecule frequency in CD4 and CD8 TEM cells from healthy women. A comparison between the frequency of (a) CCR5, (b) CCR2, (c) CCR9, (d) CCR10, (e) CXCR6, (f) αβ1, (g) α4β1, (h) α4β7, (i) CD11c and (j) CLA in CD4 (white bars) and CD8 (grey bars) effector memory T (TEM) cells was determined by flow cytometry. The frequency of each molecule was analyzed in total CD3+ TEM cells and CD38+, CD38+ HLA-DR+ or HLA-DR+ activated fractions. General gating strategy is shown in Fig 3 and S2 Fig. Each bar represents the median ± interquartile range of the mean of healthy young women (n = 13).

doi:10.1371/journal.pone.0156605.g004
In fact, the decrease of $\alpha 4$ in CD8$^+$ TEM cells was a general observation in all groups of patients (Fig 6d), which was predominantly significant in the CD38$^+$ fraction (S7 Fig). UC group characteristic profile in CD38$^+$ HLA-DR$^+$ TEM cells was an increase of $\alpha 1$ percentage in CD4$^+$ TEM cells (as occurred in the PS group) (Fig 6c). Lastly, the BV group shared the decrease in the percentage of $\alpha 4$ expression in CD8$^+$ TEM cells with the PS group. As for the unique features in BV patients, we detected higher frequency of CCR5 and $\alpha 4$ in CD4$^+$ TEM cells with a concomitant decrease in the frequency of $\alpha 4$ in these cells, and also exclusive high percentage of CD11c in CD8$^+$ TEM cells (Fig 6). In summary, increased expression of CCR5 and CD11c on CD4$^+$ and CD8$^+$ TEM cells respectively was confirmed in women with symptomatic BV.

CD11c expression in blood after vaginal infection correlates with an increase in the genital tract but is not exclusive of infection in these tissues

Considering that CD11c was the most striking and novel marker of genital tract condition in both, mice and women, we performed additional experiments to address if this increase was exclusive of productive infection in these tissues or, in contrast, was a consequence of bacterial infection in general. Therefore, we performed a new set of animal experiments in which we included an intravenously (IV) Chlamydia-infected group. It is important to note that IV infection induces bacterial replication in different systemic and also mucosal tissues, including spleen and lung [21]. Interestingly, seven days post-infection the frequency of CD11c$^+$ cells on blood T cells was much higher in the IV group (median: 13.1% [IQR: 10.9–16.3]) than in any other group (median: 1.5% [IQR: 0.9–2.2] in the controls or median: 5.23% [IQR: 3.4–8.4] in the VAG group) (Fig 7). In the control and the VAG groups we obtained cell suspensions from the genital tract to determine the frequency of CD11c$^+$ T cells. As shown (Fig 7), seven days after infection, the total frequency of CD3$^+$ CD11c$^+$ in genital tract increased from a median of
0.46% [IQR: 0.28–0.74] in the control group to a median of 4.43% [IQR: 2.68–5.33] in the VAG group. Additional assessment of the expansion of CD11c+ CD44+ cells in different tissues, including spleen, draining lymph nodes (dLNs), blood and genital tract of the VAG infected animals 14 days post-infection demonstrated that most of these cells are CD8+ that expand in spleen, blood and, mainly, in the genital tract (Fig 8). This way, while CD11c+ CD44+ represented 0.37% [IQR: 0.47–0.85] of the CD4+ cells in spleen, 0.61% [IQR: 0.40–0.82] in dLNs, 0.83% [IQR: 0.17–0.41] in blood and 4.2% [IQR: 2.3–4.7] in genital tract of the VAG-infected mice, these CD11c+ CD44+ cells were more frequent in the CD8+ cell fraction from all these tissues: 6.4% [IQR: 6.3–10] in the spleen, 1.9% [IQR: 1.5–2.1] in the dLNs, 23% [IQR: 15–42] in blood and 53% [IQR: 46–53] in the genital tract. Thus, 7 and 14 days after infection, CD11c expression increases in the genital tract of mice correlating with the increase observed in blood. However, CD11c increased expression is not specific to infection in the genital tract, since systemic infection also expands this subset.

### Discussion

We interrogated the expression of multiple adhesion molecules in circulating T_{EM} cells from different groups of women with disorders affecting primarily peripheral tissues. We report for the first time that women with BV have higher frequency of CD8+ T_{EM} expressing CD11c. This
increase was not observed during inflammatory pathologies affecting the gastrointestinal tract or the skin. Importantly, we also detected an increase in CD11c gene and protein expression in a mouse model of *Chlamydia* reproductive tract infection in both, blood and genital tract. Other patterns of integrin and chemokine receptor expression were also observed in patients with BV. In particular, the expression of CCR5 and α4β1 was increased in circulating CD4+ TEM cells of these women compared to healthy donors.

The increased expression of CD11c in TEM cell subsets soon after vaginal infection or during an episode of vaginosis was a strong and consistent finding in mice and women. Although the expression of CD11c has been classically used to identify dendritic cells, this α-chain integrin is also expressed in other myeloid cells, NK cells and populations of activated T and B cells [28]. Specifically within the activated T cell fraction, CD11c expression has been associated to effector and regulatory T cells in different mouse models [29–33], as well as with intraepithelial lymphocytes in the small gut [34, 35]. More recently, some authors have described the existence of a unique subset in mice and importantly, in humans, that combine key features of T and dendritic cells [36]. These cells are positive for T cell receptor, major histocompatibility complex II and CD11c+ and, regardless of their lymphocyte morphology, posses antigen presenting cell and innate-like properties [36]. However, to our knowledge, no specific report on expression of CD11c in human T cells in association to a mucosal condition has ever been published.

A considerable constraint in our study is the comparison between the cohorts evaluated. Although all these disorders have a clear Th1 component [37–39], they have very different...
origins and associated inflammation, and no other mucosal disorder with a bacterial component could be compared to the BV group. This fact, the Chlamydia systemic infection experiment results (Fig 7) and supporting animal models that demonstrate CD11c expression in T cells after systemic vaccination and infection [29–33], indicates that CD11c expression is not specific to genital tract infection, rather indicative of activation and recirculation in general.
Moreover, there was a trend towards higher percentage of CD11c+ in T cells from patients with UC that was significant in the HLA-DR fraction (S8 Fig). Although we acknowledge the limitation of the sample size for the cohorts included in the study, the present results represent a unique comparison between peripheral tissue alterations that provide adhesion molecules of interest for each of the different disorders to further explore. In any case, this is the first report demonstrating enhanced CD11c expression in CD8+ TEM cells after intravaginal *Chlamydia* infection in mice and symptomatic BV in women, and we are currently working on defining the phenotype and role of these cells in these models.

The differential expression of certain adhesion molecules can induce a site-dependent homing profile that may work together with some other generic signals (such as CXCR3, CCR3, CCR5 and CCR6) [10]. Previous studies have examined adhesion molecules necessary for homing to the upper genital tract in a mouse model of *C. trachomatis* infection by directly infecting the uterine horns [14, 40]. In this model, CXCR3, CCR5 and α4β1 are required for homing of protective T cells to the murine upper genital tract [14, 40]. Interestingly, samples from women with symptomatic BV, confirmed two of these molecules as potentially involved in FGT homing in humans. The frequency of integrin α4β1 was indeed up regulated in CD4+ TEM cells, which correlates with high expression of this integrin in the genital mucosa of women [41]. Moreover, BV patients did also showed a higher percentage of CCR5 expression in their CD4+ TEM cells compared to ND, indicating that CCR5 might indeed be necessary for FGT homing as suggested [40]. Asymptomatic genital HSV-2 infection is also associated with increased expression of CCR5 by endocervical CD4+ T cells and similar trends were observed in circulating CD4+ T cells [18]. Further, a live-attenuated vaccine that continuously replicates in systemic and mucosal tissues in macaques also induces increased frequency of peripheral CD4+ T cells expressing CCR5, and the two animals with the highest percentage of this population had the highest number of specific T cells in the genital tract [42]. However, a recent report on the effect of vaginal immunization in women showed a clear down-regulation of CCR5 on CD4+ T cells after immunization [43]. Nevertheless, the first time-point analyzed in that study was 4 weeks post-immunization, when major recirculation and infiltration of T cells may have already occurred [12]. Of great importance is the fact that this increment is detected in the CD4+ TEM cell population, since CCR5 is a co-receptor for HIV and thus could have highly detrimental effects favoring HIV infection susceptibility [44, 45]. If higher numbers of CCR5 expressing CD4+ TEM cells are indeed infiltrated in the genital tissue during BV episodes, this could partially explain its association with higher risk of HIV-1 acquisition [46].

Finally, while CLA expression in total CD4+ TEM cells of the PS group was unexpectedly reduced compared to ND (S1c Fig), we detected higher frequency of CLA on CD8+ HLA-DR+ TEM cells from the BV group (S8d Fig). Due to their migration to skin, the number of CLA+ T cells in the periphery decreases inversely to disease severity during acute psoriasis [47]. Further, CLA interacts with E-selectin expressed on venular endothelial cells not only from inflamed skin, but also from oral mucosa and FGT, and genital HSV-specific CD8+ T cells in the peripheral blood express high levels of CLA [16, 19]. Yet α4β7, another molecule described in asymptomatic HSV-2-infected patients but not in uninfected patients [18], was down regulated in activated TEM cells from BV patients (Fig 6). While this decrease could also indicate selective infiltration of these cells into the infected tissues early after infection, the existence of a mechanism that would actually down-regulate some of these molecules cannot be discarded.

Many properties that enable T cells to traffic to specific locations are programmed during the early stages of the infection [11]. Thus, in order to understand the homing patterns and dynamics of the mucosal response associated to vaccination and infection, we need to analyze specific and activated T cells responses early after activation [4, 12]. In summary, in this study we define adhesion molecules, namely CCR5, α4β1 and CD11c, which may be desirable to
induce in order to generate an effective mucosal response in vaccine candidates against STI. Special attention should be given to CD11c as a novel marker of T cell mucosal immunity in response to genital tract disorders.

Supporting Information

S1 Fig. Kinetics of the frequency of adhesion molecules and effector T cells after vaginal infection in mice. The frequency of CCR5 (a), CCR2 (b), CXCR6 (c), CD11c (d), CD62L-CD44+ (e) and CD62L-CD44- (f) was determined in T cells from blood by flow cytometry at 7, 10 and 14 days after vaginal infection with C. muridarum in mice. After gating on live CD3+ cells and CD4+ or CD4- (putative CD8+) T cells, the frequency of CCR5, CCR2, CXCR6, CD11c, CD62L, CD44+ and CD62L-CD44- was quantified. Each time point represents the median ± interquartile range of three or seven infected animals and all controls (n = 12). (TIF)

S2 Fig. Representative plots of adhesion molecule analysis in circulating T\textsubscript{EM} cells from women. The overall gating strategy for a representative single normal donor is shown in Fig 3. Representative plots of molecules analyzed in T\textsubscript{EM} cells in each of the panels are shown for CD4+ T\textsubscript{EM} cells (top row) and CD8+ T\textsubscript{EM} cells (bottom row): (a) expression of CCR9, α4 and β7; (b) expression of α1, β1 and CD103 and (c) expression of CCR10 and CLA. Isotype controls are shown in S3 Fig. (TIF)

S3 Fig. Isotype controls for the molecules analyzed in circulating CD4- T\textsubscript{EM} cells from women. The cut-off determined by the isotype control for each adhesion or activation molecule analyzed is shown in zebra plots for the CD4-CCR7- T cells. (TIF)

S4 Fig. Comparison of CXCR3 and CD103 frequencies in CD4 and CD8 T\textsubscript{EM} cells from healthy women. A comparison between the frequency of (a) CXCR3 and (b) CD103 in CD4 (white bars) and CD8 (grey bars) effector memory T (T\textsubscript{EM}) cells was determined by flow cytometry. The frequency of each molecule was analyzed in total CD3+ T\textsubscript{EM} cells and CD38+, CD38+HLA-DR+ or HLA-DR+ activated fractions. General gating strategy is shown in Fig 3 and S2 Fig. Each bar represents the median ± interquartile range of healthy young women (n = 13). (TIF)

S5 Fig. Frequency of CD4+ T cells during different conditions affecting peripheral tissues in women. The percentage of CD4+ T cells determined by flow cytometry is shown for ND and the different groups of patients. General gating strategy is shown in Fig 3. Each bar represents the median ± interquartile range of healthy young women (ND; white bars, n = 13), women with psoriasis (PS; grey bars, n = 5), ulcerative colitis (UC; checkered bars, n = 4) and bacterial vaginosis (BV; dark bars, n = 5). P value indicates: *<0.05. (TIF)

S6 Fig. Frequency of adhesion molecules in T\textsubscript{EM} cells from different conditions affecting women. Percentages of the expression of chemokine receptors in total (a) CD4+ effector memory T (T\textsubscript{EM}) cells and (b) CD8+ T\textsubscript{EM} cells determined by flow cytometry are shown for normal donors (ND) and the different groups of patients. Percentages of the expression of integrins and other adhesion molecules in total (c) CD4+ T\textsubscript{EM} and (d) CD8+ T\textsubscript{EM} cells determined by flow cytometry is shown for ND and the different groups of patients. General gating strategy is shown in Fig 3 and S2 Fig. Each bar represents the median ± interquartile range of healthy women.
young women (ND; white bars, n = 13), women with psoriasis (PS; grey bars, n = 5), ulcerative colitis (UC; checkered bars, n = 4) and bacterial vaginosis (BV; dark bars, n = 5). P values indicate: * < 0.05; ** < 0.01; *** < 0.001.

**S7 Fig. Frequency of adhesion molecules in CD38⁺ TEM cells from different conditions affecting women.** Percentages of the expression of chemokine receptors in CD38⁺ (a) CD4⁺ effector memory T (TEM) cells and (b) CD8⁺ TEM cells determined by flow cytometry are shown for normal donors (ND) and the different groups of patients. Percentages of the expression of integrins and other adhesion molecules in CD38⁺ (c) CD4⁺ TEM and (d) CD8⁺ TEM cells determined by flow cytometry are shown for ND and the different groups of patients. General gating strategy is shown in Fig 3 and S2 Fig. Each bar represents the median ± interquartile range of healthy young women (ND; white bars, n = 13), women with psoriasis (PS; grey bars, n = 5), ulcerative colitis (UC; checkered bars, n = 4) and bacterial vaginosis (BV; dark bars, n = 5). P values indicate: * < 0.05; ** < 0.01; *** < 0.001.

**S8 Fig. Frequency of adhesion molecules in HLA-DR⁺ TEM cells from different conditions affecting women.** Percentages of the expression of chemokine receptors in HLA-DR⁺ (a) CD4⁺ effector memory T (TEM) cells and (b) CD8⁺ TEM cells determined by flow cytometry are shown for normal donors (ND) and the different groups of patients. Percentages of the expression of integrins and other adhesion molecules in HLA-DR⁺ (c) CD4⁺ TEM and (d) CD8⁺ TEM cells determined by flow cytometry are shown for ND and the different groups of patients. General gating strategy is shown in Fig 3 and S2 Fig. Each bar represents the median ± interquartile range of healthy young women (ND; white bars, n = 13), women with psoriasis (PS; grey bars, n = 5), ulcerative colitis (UC; checkered bars, n = 4) and bacterial vaginosis (BV; dark bars, n = 5). P values indicate: * < 0.05; ** < 0.01; *** < 0.001.

**Acknowledgments**

We thank Marco A Fernández from the Flow Cytometry Platform at the IGTP for excellent technical assistance. We thank Gemma Falguera, Pilar Soteras, Edith López-Grau, Carme Uyà and Asmid Sánchez from the ASSIR at the Primary Care centers for sample collection and also Rossie Lugo from the Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT) for assistance in sample coordination with the Primary Care Centers.

**Author Contributions**

Conceived and designed the experiments: JQ LL SJM MG.Performed the experiments: JQ LL JC GR MG. Analyzed the data: JQ JC LL LS MG. Contributed reagents/materials/analysis tools: JMC EC OD. Wrote the paper: JQ JC LL SJM MG.

**References**

1. Lewis DA, Latif AS, Ndowa F. WHO global strategy for the prevention and control of sexually transmitted infections: time for action. Sexually transmitted infections. 2007; 83(7):508–9. doi:10.1136/sti.2007.028142 PMID: 18024710; PubMed Central PMCID: PMC2598641.

2. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, Wu Z, et al. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One. 2010; 5(6):e11366. Epub 2010/07/09. doi:10.1371/journal.pone.0011366 PMID: 20614067; PubMed Central PMCID: PMC2894072.
3. Genesca M. Characterization of an Effective CTL Response against HIV and SIV Infections. J Biomed Biotechnol. 2011; 2011:103924. Epub 2011/10/07. doi: 10.1155/2011/103924 PMID: 21976964; PubMed Central PMCID: PMC3184421.

4. Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol. 2010; 10(10):699–711. Epub 2010/09/11. nri2836 [pii] doi: 10.1038/nri2836 PMID: 20829886.

5. Miyairi I, Ramsey KH, Patton DL. Duration of untreated chlamydial genital infection and factors associated with clearance: review of animal studies. J Infect Dis. 2010; 201 Suppl 2:S96–103. Epub 2010/05/28. doi: 10.1086/652393 PMID: 20470047.

6. Ficarra M, Ibaña JS, Poretta C, Ma L, Myers L, Taylor SN, et al. A distinct cellular profile is seen in the human endocervix during Chlamydia trachomatis infection. Am J Reprod Immunol. 2008; 60(5):415–25. Epub 2008/09/19. AJI639 [pii] doi: 10.1111/j.1600-0897.2008.00639.x PMID: 18799835; PubMed Central PMCID: PMC2574558.

7. Genesca M, Skinner PJ, Hong JJ, Li J, Lu D, McChesney MB, et al. With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol. 2008; 82(2):11181–96. Epub 2008/09/13. JVI.01433-08 [pii] doi: 10.1128/JVI.01433-08 PMID: 18787003; PubMed Central PMCID: PMC2573271.

8. MARELLI-BERG FM, Fu H, Vianello F, Tokoyoda K, Hamann A. Memory T-cell trafficking: new directions for busy commuters. Immunology. 2010; 130(2):158–65. Epub 2010/04/23. IMM3278 [pii] doi: 10.1111/j.1365-2567.2010.03278.x PMID: 20408955; PubMed Central PMCID: PMC2878460.

9. Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nature reviews Immunology. 2010; 6(9):682–92. Epub 2008/06/26. doi: 10.1038/nri1869 PMID: 16932753.

10. Ficarra M, Engelhard VH. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J Immunol. 2010; 184(8):4079–86. Epub 2010/03/10. jimmunol.0901903 [pii] doi: 10.4049/jimmunol.0901903 PMID: 2012096; PubMed Central PMCID: PMC2887738.

11. Cauley LS, Lefrancois L. Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells. Mucosal Immunol. 2013; 6(1):14–23. Epub 2012/11/08. mi201296 [pii] doi: 10.1038/mi.2012.96 PMID: 23131785.

12. Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med. 2010; 207(3):553–64. Epub 2010/02/17. jem.20090858 [pii] doi: 10.1084/jem.20090858 PMID: 20156972; PubMed Central PMCID: PMC2839151.

13. Kelly KA, Chan AM, Butch A, Danville T. Two Different Homing Pathways Involving Integrin beta7 and E-selectin Significantly Influence Trafficking of CD4 Cells to the Genital Tract Following Chlamydia muridarum Infection. Am J Reprod Immunol. 2009. Epub 2009/04/28. AJI704 [pii] doi: 10.1111/j.1600-0897.2009.00704.x PMID: 19392981; PubMed Central PMCID: PMC2888875.

14. Davila SJ, Olive AJ, Starnbach MN. Integrin alpha4beta1 is necessary for CD4+ T cell-mediated protection against genital Chlamydia trachomatis infection. J Immunol. 2014; 192(9):4284–93. doi: 10.4049/jimmunol.1303238 PMID: 24659687; PubMed Central PMCID: PMC3995848.

15. Goodsell A, Zhou F, Gupta S, Singh M, Malyala P, Kazaz J, et al. Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology. 2008; 123(3):378–89. Epub 2007/10/20. IMM2702 [pii] doi: 10.1111/j.1600-0897.2009.00704.x PMID: 19744930; PubMed Central PMCID: PMC2433338.

16. Johansson EL, Rudin A, Wassen L, Holmgren J. Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology. 1999; 96:272–7. PMID: 10233705.

17. Youn H, Hong K, Yoo JW, Lee CH. ICAM-1 expression in vaginal cells as a potential biomarker for inflammatory response. Biomarkers. 2008; 13(3):257–69. Epub 2008/04/17. 789981735 [pii] doi: 10.1080/1354750701843338 PMID: 18415799.

18. Shannon B, Yi TJ, Thomas-Pavanel J, Chieza L, Janakiram P, Saunders M, et al. Impact of asymptomatic herpes simplex virus type 2 infection on mucosal homing and immune cell subsets in the blood and female genital tract. J Immunol. 2014; 192(11):5074–82. doi: 10.4049/jimmunol.1302916 PMID: 24760150.

19. Koelle DM, Liu Z, McClurkan CM, Topp MS, Riddell SR, Palmer EG, et al. Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest. 2002; 110(4):537–48. doi: 10.1172/JCI15537 PMID: 12189248; PubMed Central PMCID: PMC150419.

20. Scidmore MA. Cultivation and Laboratory Maintenance of Chlamydia trachomatis. Current protocols in microbiology. 2005; Chapter 11:Unit 11A 1. doi: 10.1002/9780471729259.mc11a01s00 PMID: 18770550.
21. Li LX, McSorley SJ. B cells enhance antigen-specific CD4 T cell priming and prevent bacteria dissemination following Chlamydia muridarum genital tract infection. PLoS pathogens. 2013; 9(10):e1003707. doi: 10.1371/journal.ppat.1003707 PMID: 24204262; PubMed Central PMCID: PMC3814678.

22. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005. p. 397–420.

23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545–50. doi: 10.1073/pnas.0506580102 PMID: 16199517; PubMed Central PMCID: PMC1239869.

24. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2005; 19 Suppl 1:SA–36A. PMID: 16151544.

25. Schroeder KW, Tremaine WJ, Listrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317(26):1625–9. doi: 10.1056/NEJM198712243172603 PMID: 3317057.

26. Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of resident memory CD8 (+) T cells. Nat Immunol. 2013; 14(5):509–13. doi: 10.1038/ni.2568 PMID: 23542740; PubMed Central PMCID: PMC3631432.

27. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, et al. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest. 2015; 125(5):1827–38. doi: 10.1172/JCI77990 PMID: 25822019.

28. Tan SM. The leucocyte beta2 (CD18) integrins: the structure, functional regulation and signalling properties. Bioscience reports. 2012; 32(3):241–69. doi: 10.1042/BSR20111010 PMID: 22458844.

29. Kubota K, Kadoya Y. Innate IFN-gamma-producing cells in the spleen of mice early after Listeria monocytogenes infection: importance of microenvironment of the cells involved in the production of innate IFN-gamma. Front Immunol. 2011; 2:26. Epub 2011/01/01. doi: 10.3389/fimmu.2011.00026 PMID: 22556616; PubMed Central PMCID: PMC3341966.

30. Cooney LA, Gupta M, Thomas S, Mikolajczak S, Choi KY, Gibson C, et al. Short-lived effector CD8 T cells induced by genetically attenuated malaria parasite vaccination express CD11c. Infect Immun. 2013; 81(11):4171–81. Epub 2013/08/28. IAI.00871-13 [pii]doi: 10.1128/IAI.00871-13 PMID: 23930115; PubMed Central PMCID: PMC3811835.

31. Beyer M, Wang H, Peters N, Doths S, Koerner-Rettberg C, Openshaw PJ, et al. The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res. 2005; 6:70. Epub 2005/07/14. 1465-9921-6-70 [pii]doi:10.1186/1465-9921-6-70 PMID: 16011799; PubMed Central PMCID: PMC1184101.

32. Chen Z, Han Y, Gu Y, Liu Y, Jiang Z, Zhang M, et al. CD11c(high)CD8+ regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-Fas pathway. J Immunol. 2013; 190(12):6145–54. Epub 2013/05/17. jimmunol.1300060 [pii]doi:10.4049/jimmunol.1300060 PMID: 23677464.

33. Egan CE, Craven MD, Leng J, Mack M, Simpson KW, Denkers EY. CCR2-dependent intraepithelial lymphocytes mediate inflammatory gut pathology during Toxoplasma gondii infection. Mucosal Immunol. 2009; 2(6):527–35. doi: 10.1038/mi.2009.105 PMID: 19741601; PubMed Central PMCID: PMC2860785.

34. Huleatt JW, Lefransois L. Antigen-driven induction of CD11c on intestinal intraepithelial lymphocytes and CD8+ T cells in vivo. J Immunol. 1995; 154(11):5684–93. PMID: 7751620.

35. Kuka M, Munitic I, Ashwell JD. Identification and characterization of polyclonal alpha-beta-T cells with dendritic cell properties. Nature communications. 2012; 3:1223. doi:10.1038/ncomms2223 PMID: 23187623; PubMed Central PMCID: PMC3528357.

36. Puleston J, Cooper M, Murch S, Bid K, Makh S, Ashwood P, et al. A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2005; 21(2):109–20. doi: 10.1111/j.1365-2036.2004.02262.x PMID: 15679760.

37. Terraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clinical and experimental dermatology. 2004; 29(6):658–63. doi: 10.1111/j.1365-2230.2004.01638.x PMID: 15550147.
39. Anton G, Rid J, Mylonas I, Friese K, Weissenbacher ER. Evidence of a TH1-shift of local vaginal inflammatory response during bacterial vaginosisis. Infection. 2008; 36(2):147–52. doi:10.1007/s15010-007-7152-2 PMID: 18330506.

40. Olive AJ, Gondek DC, Starnbach MN. CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol. 2011; 4(2):208–16. Epub 2010/09/17. mi201058 [pii]doi: 10.1038/mi.2010.58 PMID: 20844481; PubMed Central PMCID: PMC3010299.

41. Hladik F, Lentz G, Delpit E, McElroy A, McElrath MJ. Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5+ Th1 phenotype. J Immunol. 1999; 163 (4):2306–13. PMID: 10438976.

42. Genesca M, Skinner PJ, Bost KM, Lu D, Wang Y, Rourke TL, et al. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol. 2008; 1(3):219–28. doi: 10.1038/mi.2008.6 PMID: 19079181; PubMed Central PMCID: PMC3401012.

43. Lewis DJ, Wang Y, Huo Z, Giermza R, Babaahmady K, Rahman D, et al. Effect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women. J Virol. 2014; 88(20):11648–57. doi: 10.1128/JVI.01621-14 PMID: 25008917; PubMed Central PMCID: PMC4178755.

44. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007; 26 (2):257–70. doi: 10.1016/j.immuni.2007.01.007 PMID: 17306567; PubMed Central PMCID: PMC1885658.

45. Joag VR, McKinnon LR, Liu J, Kidane ST, Yudin MH, Nyanga B, et al. Identification of preferential CD4 (+) T-cell targets for HIV infection in the cervix. Mucosal Immunol. 2016; 9(1):1–12. doi: 10.1038/mi.2015.28 PMID: 25972482.

46. Mitchell C, Marrazzo J. Bacterial vaginosisis and the cervicovaginal immune response. Am J Reprod Immunol. 2014; 71(6):555–63. doi: 10.1111/aji.12264 PMID: 24832618; PubMed Central PMCID: PMC4128638.

47. Ferran M, Gimenez-Arnau AM, Bellosillo B, Pujol RM, Santamaría-Babi LF. Circulating CLA+ T cell subsets inversely correlate with disease severity and extension in acute psoriasis but not in chronic plaque psoriasis. European journal of dermatology: EJD. 2008; 18(6):647–50. doi: 10.1684/ejd.2008.0513 PMID: 18955198.